Jazz Pharmaceuticals PLC at Cowen HealthCare Conference Transcript
Thank you for your time this morning. I'll just say, I will make forward-looking statements. You'll see our risk factors on our SEC filings, and I may refer to adjusted GAAP numbers, and we always provide a reconciliation on our website.
So it's been a productive start to 2020 for Jazz. In addition to just announcing our 2019 results and our 2020 guidance, we've had a product approved, submitted an NDA and had another NDA accepted for filing with priority review. So that puts us well on track to achieve our objective of launching 4 new products in the next 18 months or so. So a real catalyst-rich time for the company, and we'll look forward to continuing to demonstrate through our regulatory progress, our development progress, our commercial progress, how we're diversifying the top line for sustainable growth.
Coronavirus, my favorite topic. I'll just say no direct impact to us thus far. When we think about impact to the business, we start with impact to patients, making sure we can supply product on a reliable
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |